Mosaic RNA Phage VLPs Carrying Domain III of the West Nile Virus E Protein

Cielēns, Indulis; Jackevica, Ludmila; Strods, Arnis; Kazāks, Andris; Ose, Velta; Bogans, Jānis; Pumpens, Paul; Renhofa, Regīna

doi:10.1007/s12033-014-9743-3

Cited by 13 publications

(9 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AP205-DIII mosaic VLPs were generated by displaying a 111-amino acid WNV EDIII on the surface of AP205 VLPs, and expressing them in the E.coli system. These VLPs stimulated anti-DIII responses in mice with high-level IgG2 isotype antibodies [95], suggesting the possibility of development of AP205-DIII VLPs as a promising West Nile vaccine. Similar to DENV VLPs, CD16-RIgE can be used as a platform to display WNV EDIII on the surface of VLPs, which induced neutralizing antibodies in mice [89].…”

Section: Factors Affecting the Production Or Packaging Of Denv Vlpsmentioning

confidence: 97%

Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines

Zhang

Jiang

et al. 2020

Vaccines

View full text Add to dashboard Cite

Flaviviruses include several medically important viruses, such as Zika virus (ZIKV), Dengue virus (DENV), West Nile virus (WNV) and Japanese encephalitis virus (JEV). They have expanded in geographic distribution and refocused international attention in recent years. Vaccination is one of the most effective public health strategies for combating flavivirus infections. In this review, we summarized virus-like particle (VLP)-based vaccines against the above four mentioned flaviviruses. Potential strategies to improve the efficacy of VLP-based flavivirus vaccines were also illustrated. The applications of flavivirus VLPs as tools for viral detection and antiviral drug screening were finally proposed.

show abstract

Section: Factors Affecting the Production Or Packaging Of Denv Vlpsmentioning

confidence: 97%

Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines

Zhang

Jiang

et al. 2020

Vaccines

View full text Add to dashboard Cite

show abstract

“…Even though AP205 VLPs are under investigation as carrier for various vaccine candidates (24)(25)(26)(27)(28)(29), no safety data in humans is available, and such lack of clinical information can slow down the development of new vaccines based on this VLP platform. By contrast, using a VLP with a well-established safety profile as a vaccine scaffold could accelerate the pre-clinical to clinical transition.…”

Section: Introductionmentioning

confidence: 99%

A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response

Marini

Zhou

et al. 2019

Front. Immunol.

View full text Add to dashboard Cite

Development of effective malaria vaccines requires delivery platforms to enhance the immunogenicity and efficacy of the target antigens. This is particularly challenging for transmission-blocking malaria vaccines (TBVs), and specifically for those based on the Pfs25 antigen, that need to elicit very high antibody titers to stop the parasite development in the mosquito host and its transmission. Presenting antigens to the immune system on virus-like particles (VLPs) is an efficient way to improve the quantity and quality of the immune response generated. Here we introduce for the first time a new VLP vaccine platform, based on the well-established hepatitis B surface antigen (HBsAg) fused to the SpyCatcher protein, so that the antigen of interest, linked to the SpyTag peptide, can be easily displayed on it (Plug-and-Display technology). As little as 10% of the SpyCatcher::HBsAg VLPs decorated with Pfs25::SpyTag (molar ratio) induces a higher antibody response and transmission-reducing activity in mice compared to the soluble protein, with 50 and 90% of the VLP coupled to the antigen further enhancing the response. Importantly, using this carrier that is a vaccine antigen itself could be beneficial, as we show that anti-HBsAg IgG antibodies are induced without interfering with the Pfs25-specific immune response generated. Furthermore, pre-existing anti-HBsAg immunity does not affect the antigen-specific response to Pfs25::SpyTag-SpyCatcher::HBsAg, suggesting that these VLPs can have a broad use as a vaccine platform.

show abstract

“…The peak fractions were analysed using SDS-PAGE, native agarose gel electrophoresis, dynamic light scattering (DLS), and electron microscopy (EM). DLS analysis was performed on a Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK), in line with previously described VLP measurements [28] . The results were analysed by DTS software (Malvern, version 6.32).…”

Section: Methodsmentioning

confidence: 99%

Silica Nanoparticles as the Adjuvant for the Immunisation of Mice Using Hepatitis B Core Virus-Like Particles

et al. 2014

Self Cite

View full text Add to dashboard Cite

Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10–20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund's adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component.

show abstract

Mosaic RNA Phage VLPs Carrying Domain III of the West Nile Virus E Protein

Cited by 13 publications

References 59 publications

Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines

Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines

A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response

Silica Nanoparticles as the Adjuvant for the Immunisation of Mice Using Hepatitis B Core Virus-Like Particles

Contact Info

Product

Resources

About